FindTrial
Sign In

MEDI0562

BIOLOGICAL3 trials

Sponsors

MedImmune LLC, Providence Health & Services

Conditions

Advanced Solid TumorsCarcinoma, Squamous CellCell Cancer, SquamousHead and Neck CancerHead and Neck Squamous Cell CarcinomaMelanomaSelect Advanced Solid Tumors

Phase 1

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
CompletedNCT02318394
MedImmune LLCAdvanced Solid Tumors
Start: 2015-03-02End: 2018-01-09Updated: 2018-01-29
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
CompletedNCT02705482
MedImmune LLCSelect Advanced Solid Tumors
Start: 2016-03-30End: 2019-08-07Updated: 2019-08-26
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
CompletedNCT03336606
Providence Health & ServicesCarcinoma, Squamous Cell, Cell Cancer, Squamous, Head and Neck Cancer +2
Start: 2018-07-25End: 2026-05-14Updated: 2026-05-22

Related Papers

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Journal of Clinical Oncology2020-05-2014 citations
Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
Annals of Oncology2018-10-0122 citations
A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.
Journal of Clinical Oncology2017-05-203 citations
A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Journal of Clinical Oncology2015-05-209 citations